Posted Date: 4/17/2017

Nabriva Therapeutics Announces Enrollment Completion for Phase 3 Clinical Trial

Nabriva Therapeutics AG recently announced it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. LEAP 1, which is designed to assess the efficacy and safety of lefamulin (IV/oral) compared to moxifloxacin (IV/oral) in patients with moderate-to-severe community-acquired bacterial pneumonia (CABP), met its enrollment target of 550 patients. The company anticipates availability of top-line clinical data from LEAP 1 in the third quarter of 2017.

“This is a potentially transformational year for Nabriva with the completion of enrollment for LEAP 1 and top-line clinical data anticipated in the third quarter,” said Dr. Colin Broom, Chief Executive Officer of Nabriva. “We will continue to enroll our second pivotal Phase 3 clinical trial, LEAP 2, which is evaluating efficacy and safety of oral lefamulin for the treatment of patients with moderate CABP.  Based on current projections, we expect to complete patient enrollment for LEAP 2 in the fourth quarter of 2017 and anticipate availability of top-line data for LEAP 2 in the first quarter of 2018.”

“Bacterial resistance to commonly prescribed antibiotics for the treatment of CABP continues to rise globally, rendering those antibiotics less effective and increasing the need for new classes of therapies,” said Elyse Seltzer, MD, Chief Medical Officer of Nabriva Therapeutics. “As the potential first-in-class pleuromutilin available for systemic administration in humans, lefamulin could provide a monotherapy for patients with moderate-to-severe CABP, with targeted activity against the most common pathogens, including multidrug resistant strains. Additionally, we believe that it is critically important to develop antibiotics that align with the principles of antibiotic stewardship and offer a new, targeted option for the empiric treatment of these patients. We look forward to sharing the results from this trial with the scientific and medical communities.”

Based on a combined analysis of the US Centers for Disease Control and Prevention’s 2007 National Ambulatory Medical Care Survey, the National Hospital Ambulatory Medical Care Survey and 2013 data from the Healthcare Cost and Utilization Project, Nabriva estimates that over 5 million adults are treated annually for CABP in the US.  Additionally, based on 2013 data from the Healthcare Cost and Utilization Project, Nabriva estimates that approximately 3 million of these adult CABP patients are diagnosed in an in-patient hospital and/or emergency department setting, where most are then treated with in-patient IV and oral antibiotics or out-patient oral antibiotics prescribed for use following hospital discharge or release.

Nabriva’s first pivotal Phase 3 clinical trial, LEAP 1, is a multi-center, randomized, controlled, double-blind, international study comparing lefamulin to moxifloxacin, a fluoroquinolone antibiotic. LEAP 1 is designed to evaluate the efficacy and safety of lefamulin (IV/oral) compared to moxifloxacin (IV/oral), with or without linezolid, in 550 patients with moderate to severe CABP. Linezolid (or matching placebo for the lefamulin arm) can be added to treatment if an investigator suspects that a patient is infected with methicillin-resistant S. aureus (MRSA) prior to randomization, as moxifloxacin is not approved to treat MRSA. All patients enrolled in this trial have a Pneumonia Outcomes Research Team (PORT) severity of at least 3 on a scale of 1 to 5, which corresponds to moderate-to-severe clinical disease. Nabriva’s second pivotal Phase 3 clinical trial, LEAP 2, is a multi-center, randomized, controlled, double-blind, international study comparing oral lefamulin to moxifloxacin. LEAP 2 is designed to evaluate the efficacy and safety of oral lefamulin compared to oral moxifloxacin in subjects with moderate CABP. All patients enrolled in this trial have a PORT severity of 2 to 4 on a scale of 1 to 5, which corresponds to moderate disease. Nabriva is targeting the enrollment of approximately 738 patients in LEAP 2. Both Phase 3 clinical trials of lefamulin were designed to follow draft guidance published by the US FDA for the development of drugs for CABP and guidance from the European Medicines Agency for the development of antibacterial agents.

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Lefamulin is currently being evaluated in two global, registrational Phase 3 clinical trials in patients with moderate-to- severe CABP. Nabriva believes lefamulin is well-positioned for use as a first-line empiric monotherapy for the treatment of moderate-to-severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral, and IV formulations and a favorable tolerability profile. Nabriva Therapeutics intends to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Nabriva Therapeutics owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the US, Europe, and Japan.

Related Taxonomy
Popularity:
This record has been viewed 1121 times.





















- SHL


Click here to see the showcases


BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
 
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

AAPS
November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
 
PDA Annual Meeting
March 19-21 Orlando, FL
 
CPhI North America
April 24-26 Philadelphia, PA 
 
INTERPHEX
April 17-19 New York City
 
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
 
BIO 2018
June 4-7 Boston, MA
 
Controlled Release Society Meeting
July 23-25 New York City
 
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL
 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions